Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
Opus Genetics, Inc. Study met its primary and key secondary endpoints, demonstrating rapid and sustained improvement in near…